Ironwood Pharmaceuticals, Inc.  

(Public, NASDAQ:IRWD)   Watch this stock  
Find more results for irwd
15.40
-0.48 (-3.02%)
After Hours: 15.73 +0.33 (2.15%)
Sep 29, 4:24PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.30 - 15.83
52 week 7.35 - 16.17
Open 15.83
Vol / Avg. 906,374.00/1.12M
Mkt cap 2.21B
P/E     -
Div/yield     -
EPS -0.67
Shares 129.78M
Beta 1.60
Inst. own 109%
Nov 1, 2016
Q3 2016 Ironwood Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 12, 2016
Ironwood Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference - Webcast
Sep 7, 2016
Ironwood Pharmaceuticals Inc at Wells Fargo Securities Healthcare Conference
Aug 4, 2016
Q2 2016 Ironwood Pharmaceuticals Inc Earnings Call
Aug 4, 2016
Q2 2016 Ironwood Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -39.93% -95.40%
Operating margin -28.18% -68.26%
EBITD margin - -48.71%
Return on average assets -13.36% -30.08%
Return on average equity -101.03% -155.35%
Employees 474 -
CDP Score - -

Address

301 Binney St
CAMBRIDGE, MA 02142-1030
United States - Map
+1-617-6217722 (Phone)
+1-617-4940480 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company's products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. It operates through human therapeutics segment. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. It is engaged in developing therapeutic platforms for the treatment of vascular and fibrotic diseases, and refractory gastroesophageal reflux disease (GERD). Its IW-9179 is used for the treatment of gastroparesis and functional dyspepsia. The Company has conducted an exploratory Phase IIa clinical study of IW-3718 in patients with refractory GERD. It has two sGC development candidates, which include IW-1973 and IW-1701.

Officers and directors

Peter M. Hecht Ph.D. Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Thomas Graney Chief Financial Officer, Senior Vice President - Finance, Corporate Strategy
Age: 51
Bio & Compensation  - Reuters
Mark G. Currie Ph.D. Senior Vice President, Chief Scientific Officer, President - Research and Development
Age: 61
Bio & Compensation  - Reuters
Thomas A. McCourt Senior Vice President - Marketing and Sales, Chief Commercial Officer
Age: 58
Bio & Compensation  - Reuters
Halley E. Gilbert Esq. Senior Vice President, Chief Legal Officer, Secretary
Age: 46
Bio & Compensation  - Reuters
Andrew Dreyfus Director
Bio & Compensation  - Reuters
Marsha H. Fanucci Independent Director
Age: 62
Bio & Compensation  - Reuters
Terrance G. McGuire Independent Director
Age: 59
Bio & Compensation  - Reuters
Julie H. McHugh Independent Director
Age: 50
Bio & Compensation  - Reuters
Lawrence S. Olanoff M.D. Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters